Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026
Drug Combination Shows Promise Against Treatment-Resistant Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxA University of Michigan study suggests that combining two types of drugs could offer a new approach to treating advanced, treatment-resistant prostate cancer. The research focused on tumors that have changed their identity through a process called transdifferentiation. These tumors can become more aggressive and may no longer respond well to standard treatments that target […]
How Prostate Cancer Hijacks Amino Acids to Beat Hormone Therapy
/in Preclinical Research/by MaxProstate cancer cells can outsmart hormone therapy by rewiring how they use nutrients, and a new preclinical study from Weill Cornell Medicine shows exactly how. Published in Nature Metabolism, the work reveals that tumors hijack the metabolism of two common amino acids, isoleucine and valine, to boost cholesterol production inside the tumor. That extra cholesterol […]
pTVG-HP DNA Vaccine Shows Long-Term Survival Benefit in Recurrent Prostate Cancer
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxLong-term follow-up from a randomized phase 2 trial suggests that the DNA vaccine pTVG-HP (MVI-816) may significantly extend overall survival in men with PSA-recurrent, non-metastatic, castration-sensitive prostate cancer. The findings are particularly notable because the vaccine did not improve the study’s original primary endpoint of 2-year metastasis-free survival. The trial enrolled 99 men whose prostate […]
UPDATE: PGV001 Trial Focused on Prostate Cancer
/in Clinical Trial, Non-Metastatic, Phase 1/by MaxMount Sinai is testing a personalized vaccine designed to help the immune system recognize and attack residual prostate-cancer cells. The phase 1 trial is evaluating PGV001, a multi-peptide vaccine created from each patient’s own tumor mutations, in combination with CDX-301, a cytokine intended to strengthen the immune response. Unlike a preventive vaccine, this is a […]
Phase 1/2 Trial for CRG-150, a New Approach to Immunotherapy
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxCRG-150 is entering first-in-human testing as an unconventional immunotherapy for patients with relapsed or refra9ctory metastatic prostate cancer and other solid tumors. The autologous, CRISPR-edited cell therapy targets steroid receptor coactivator 3, or SRC-3, in regulatory T cells. Tregs help maintain immune tolerance but can suppress antitumor immunity in prostate cancer. By disrupting SRC-3, CRG-150 […]
SCD1 Inhibition May Strengthen Enzalutamide Against Resistant Prostate Cancer
/in Preclinical Research/by MaxSCD1 is an enzyme that helps prostate-cancer cells convert saturated fatty acids into monounsaturated fatty acids, which support cell membranes, energy storage and survival signaling. Functional research suggests that some tumors rely on SCD1 activity. Blocking this pathway can disrupt lipid synthesis, androgen-receptor signaling and survival pathways such as AKT. This provides the rationale for […]
Phase 1 Trial: Boosting Sipuleucel‑T with N‑803
/in Clinical Trial, Metastatic, Phase 1/by MaxFifteen years after sipuleucel‑T became the first cellular immunotherapy to show an overall‑survival benefit in metastatic castration‑resistant prostate cancer (mCRPC), a new phase Ib trial at Washington University is testing whether adding the IL‑15 superagonist N‑803 (Anktiva) can turn that modest, durable survival signal into a stronger, more consistent immune attack on metastatic disease. The […]
Low 10-Year Prostate Cancer Mortality Across All Treatments: Long-Term CEASAR Data Reinforce Shared Decision-Making
/in Observational/by MaxA decade after diagnosis, most men with localized prostate cancer are far more likely to die of something else than of their cancer, regardless of whether they choose surgery, radiation, or active surveillance. This is the central message of the long-term follow-up from the CEASAR study, a large, prospective, observational population-based U.S. cohort that enrolled […]